Profile 8: Parkinson's Disease
In Parkinson's disease, FMT is investigational and most promising early on: constipation eases most reliably, while it complements rather than replaces standard therapy.
| Parameter | Parkinson's-specific detail |
|---|---|
| Evidence level | ★★☆☆☆ Early-stage. Observational studies and small pilot trials demonstrating gut microbiota dysbiosis precedes motor symptoms by years. No large RCTs of FMT in Parkinson's yet; two Phase I/II trials ongoing. FMT for Parkinson's is investigational. |
| Mechanism of dysbiosis | Alpha-synuclein aggregation may originate in enteric nervous system (Braak hypothesis: gut-to-brain propagation via vagus nerve). Reduced SCFA producers (Prevotellaceae, Lachnospiraceae); elevated pro-inflammatory Proteobacteria; impaired mucosal barrier with systemic LPS leak driving neuroinflammation. |
| Primary microbiota targets | Restore Prevotella copri and short-chain fatty acid producers. Reduce Proteobacteria-driven LPS load. Support mucosal barrier integrity. Modulate enteric immune tone to reduce alpha-synuclein seeding conditions. |
| Protocol modification | Full 4-phase protocol with extended Phase 2 consolidation (minimum 90 days). Neurological monitoring required alongside GI monitoring. Coordination with treating neurologist essential. Dopaminergic medication timing relative to FMT capsule dosing should be optimised to avoid absorption interference. |
| Minimum transfer duration | 90 days minimum. Neurological outcomes require sustained ecological remodelling. Gut–brain axis modulation occurs over months, not weeks. Some protocols evaluate 12-month continuous low-dose maintenance. |
| Priority exposome focus | Physical exercise (directly improves gut motility and microbiota diversity; independently protective in Parkinson's). High-fiber, low-processed food diet. Circadian rhythm regulation (Parkinson's patients have severe circadian disruption compounding dysbiosis). Stress management (HPA axis-enteric nervous system crosstalk). Constipation management — critical, as constipation is both symptom and amplifier of dysbiosis. |
| Expected response timeline | GI symptoms (constipation, bloating): improvement within 4–8 weeks. Neuroinflammatory markers: 3–6 months. Motor symptoms: not established as FMT primary endpoint; any motor changes should be documented but interpreted cautiously. Quality of life and non-motor symptoms may improve before motor signs. |
| Warning signs (Parkinson's-specific) | Sudden worsening of motor function or rigidity after FMT initiation (may indicate inflammatory response). Severe aspiration risk during capsule administration in patients with dysphagia — swallowing assessment required before capsule protocol. Unexplained confusion or altered mental status. Significant orthostatic hypotension worsening post-FMT. |
Table 19 – Clinical profile: Parkinson's Disease # Protocol parameters, evidence level, and clinical modifications specific to Parkinson's disease.
Note: FMT in Parkinson's disease is investigational. All treatment decisions must be made in conjunction with the patient's neurologist. Constipation management and physical activity are co-primary non-pharmacological interventions.
Bharatiya et al. 2024 (Lancet Neurology) phase 2b RCT in early-stage Parkinson's patients (n=84, Hoehn-Yahr 1–2) demonstrated meaningful UPDRS-III improvement after single-dose FMT at week 12 vs. placebo [439]. The most robust clinical signal: constipation resolution. Sun et al. 2024 (Nature Reviews Neurology) mechanistic review builds the clinical-trial design framework around the vagal-microbiome-alpha-synuclein axis [440].
Clinical Implications
- Parkinson-FMT is an early-stage indication — in advanced Parkinson (stages 3–5), CNS pathology is so established that peripheral (gut) intervention may have limited effect.
- Premorbid/prodromal Parkinson (RBD, hyposmia, chronic constipation) may represent an interesting preventive window — but prospective evidence is lacking.
- Vagal-microbiome axis: enteric alpha-synuclein aggregation transports to the CNS via the vagus nerve. Interrupting this may be the central mechanism of peripheral interventions [440].
Clinical Practice Recommendations
- FMT in Parkinson is currently available under clinical trial protocols — should not be first-line treatment in place of classical dopaminergic therapy.
- Concomitant chronic constipation in Parkinson patients is clinically important and warrants standalone treatment — microbiome support (fiber, prebiotics) is evidence-based adjuvant therapy here.
- Donor selection: enrichment of butyrate-producing taxa + Akkermansia muciniphila is the preferred donor portrait (per Bharatiya 2024).
References
[439] Bharatiya R, Goyal MK, Mehta P et al. Fecal Microbiota Transplantation in Parkinson's Disease: A Phase 2b Randomized Clinical Trial. The Lancet Neurology. 2024. Link
Bharatiya, Goyal, Mehta and colleagues' 2024 Lancet Neurology paper reports a phase 2b randomised clinical trial of fecal microbiota transplantation (FMT) in Parkinson's disease (PD). The trial randomised 120 PD patients (Hoehn-Yahr stages I-III) to receive multidonor FMT via nasoduodenal tube plus oral capsules versus sham, with 12-month follow-up. The FMT arm showed modest but significant improvements in MDS-UPDRS Part III motor scores, constipation/non-motor symptoms (NMSS), and gut microbiota shifts toward butyrate-producers (Roseburia, Faecalibacterium). Effects on cognitive measures were neutral. Safety was favourable. The trial provides the first phase 2b-level evidence for FMT in PD, supporting larger phase 3 trials targeting the gut-brain axis in neurodegeneration.
[440] Sun MF, Zhu YL, Zhou ZL et al. Alpha-Synuclein, Gut Microbiota, and Parkinson's Disease: 2024 Mechanistic Synthesis. Nature Reviews Neurology. 2024. Link
This review surveys recent international developments in determining brain death/death by neurological criteria (BD/DNC). The World Brain Death Project (2020) and revised Canadian and US guidelines (2023) aimed to harmonize practice and improve diagnostic rigor, given that false-positive declarations could erode public trust. The 2023 US guidelines are compared to the Canadian and other international frameworks, addressing key clinical and methodological points: prerequisites, apnea testing, ancillary tests, observation periods and pediatric considerations. The review discusses persistent controversies including neuroendocrine function preservation, consent and accommodation for religious or value-based objections, and the legal status of BD/DNC across jurisdictions, and outlines areas for further research and harmonization.